Middle East Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarker (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays), By End Use, By Region, And Segment Forecasts, 2025 - 2033

Middle East Renal Biomarkers Market Summary

The Middle East renal biomarkers market size was estimated at USD 191.23 million in 2024 and is projected to reach USD 399.33 million by 2033, growing at a CAGR of 8.67% from 2025 to 2033. The burden of kidney disease is increasing steadily across the Middle East, driven by high rates of diabetes, hypertension, and obesity. Chronic kidney disease (CKD) and acute kidney injury (AKI) are emerging as major public health concerns, creating a growing need for earlier and more accurate detection methods beyond conventional testing. CKD often progresses silently until advanced stages, which makes biomarker-based diagnostics especially valuable for early intervention. In January 2025, Biomed Central highlighted a recent population-based study in the Kingdom of Saudi Arabia that reported an overall prevalence of chronic kidney disease (CKD) of 4.76% (95% CI: 4.72-4.80%) among adults tested between 2015 and 2022.

Reports from the International Society of Nephrology (ISN) Global Kidney Health Atlas in 2024, as well as other studies, highlight that the Middle East and North Africa (MENA) regions have a high prevalence of CKD risk factors, including diabetes, obesity, and hypertension. This high burden underscores the urgent need for more effective early diagnostic tools, including advanced renal biomarkers, to enhance patient outcomes. The International Society of Nephrology Global Kidney Health Atlas reports that in the Middle East region, the prevalence of CKD ranged from ~5.24% to ~10.57% among different countries. Further, for the end‐stage kidney disease (ESKD) treated with renal replacement therapy in the Gulf region: one study in the GCC found a mean prevalence of ESKD of 551 per million population (pmp), with country‐specific extremes such as Oman (~1000 pmp) and Qatar (~347 pmp).

In July 2025, Serum KIM-1 and Cystatin C levels were assessed as early biomarkers for kidney injury by a study that included participants from Middle East University (MEU) and Al-Yarmouk University. According to the snippet's source, another study examined the use of serum KIM-1 as an early diagnostic marker for diabetic nephropathy and found markedly elevated levels in diabetic groups. This study may have involved researchers or institutions from the Middle East. In addition to being a biomarker for acute kidney injury (AKI), studies have shown that KIM-1 serves as an entry point for several enveloped viruses, including the Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. Given the origin of MERS-CoV, this emphasizes a particular regional relevance for KIM-1 research.

The Middle East renal biomarkers industry is gradually moving toward advanced laboratory automation and precision diagnostic systems. Hospitals and reference labs in Saudi Arabia and the United Arab Emirates are adopting automated analyzers and multiplex immunoassays that enhance detection accuracy and reduce turnaround times. The integration of advanced chemistry analyzers, AI-based data interpretation, and cloud-linked laboratory information systems is allowing clinicians to identify kidney damage at earlier stages. International diagnostic companies are also expanding their regional partnerships, providing access to innovative biomarker panels, such as NGAL, KIM-1, and cystatin C, which help detect subclinical kidney injury before it becomes irreversible.

Saudi Arabia and the UAE are leading the region in healthcare infrastructure. Both countries have invested heavily in modern hospitals, laboratories, and digital health systems that enable advanced diagnostic testing. Kuwait closely follows with well-equipped tertiary hospitals and a growing network of diagnostic services. Oman and Qatar are enhancing their diagnostic infrastructure, but access to high-end testing remains limited outside major cities.

Middle East Renal Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East renal biomarkers market based on biomarker, diagnostic technique, end use, and region:

• Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
• Functional Biomarkers
• Serum Creatinine
• Blood Urea Nitrogen (BUN)
• Estimated Glomerular Filtration Rate (eGFR)
• Upregulated Proteins
• Kidney Injury Molecule-1 (KIM-1)
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Cystatin C
• Interleukin-18 (IL-18)
• Others
• Other Novel Biomarkers
• microRNA biomarkers
• Proteomic/metabolomic markers
• Diagnostic Technique/Platform Outlook (Revenue, USD Million, 2021 - 2033)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunoassays
• Clinical Chemistry Assays
• Point-of-Care Testing (POCT) Devices
• Molecular Diagnostics
• Other Emerging Platforms
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• Middle East
• Saudi Arabia
• UAE
• Kuwait
• Oman
• Qatar

Please note The report will be delivered in 2-3 business days upon order notification. Show more